ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors — Recruiting • Phase I / Phase II • Oncology • NCT06618287.
- Trial testing safety and early effectiveness of BMS-986507 combined with other drugs in adults with advanced cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors. Conditions: Lung Cancer, Breast Cancer Interventions: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig Lead Sponsor: Bristol-Myers Squibb Planned Enrollment: 416 participants